PPARG and endothelial dysfunction: Consistent with this data, McCarthy and coworkers demonstrated that administration of a PPARγ antagonist (T0070907) to pregnant rats led to endothelial dysfunction, reduced expression of VEGF, and increased levels of plasma soluble VEGF receptor-1 (sVEGFR-1), which acts as a VEGF scavenger [38].